Claims for Patent: 12,433,862

Summary for Patent: 12,433,862

Title:	Pharmaceutical compositions and uses directed to lysosomal storage disorders
Abstract:	The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
Inventor(s):	Michael Strupp
Assignee:	Intrabio Ltd
Application Number:	US17/854,027
Patent Claims:	1. A method of treating a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD in a subject in need thereof comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria. 2. A method of delaying progression of a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD over time as compared to typical disease progression in a subject in need thereof comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria. 3. A method of reversing progression of a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD over time in a subject in need thereof comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria. 4. A method of improving in a subject in need thereof a biochemical marker of a lysosomal storage disorder (LSD) over time comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria. 5. A method of providing neuroprotection in a subject having, suspected of having, or at risk of having a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD comprising: administering a therapeutically effective amount about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria. 6. The method according to claim 4, wherein the biochemical marker is increased lysosomal volume. 7. The method according to claim 1, wherein the subject is asymptomatic. 8. The method according to claim 4, wherein the initial administration occurs after the subject has been found to have a genetic and/or biochemical marker of the LSD. 9. The method according to claim 1, wherein the acetyl-leucine is acetyl-DL-leucine. 10. The method according to claim 1, wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer. 11. The method according to claim 1, wherein the acetyl-leucine is in a single enantiomeric form of either the L-enantiomer or the D-enantiomer. 12. The method according to claim 11, wherein the single enantiomeric form is the L-enantiomer. 13. The method according to claim 1, wherein the method comprises administering the acetyl-leucine to the subject in need thereof at a therapeutically effective amount of from about 500 mg to about 15 g per day. 14. The method according to claim 1, wherein the LSD is chosen from Niemann-Pick type A disease, Niemann-Pick type B disease, and Niemann-Pick type C disease. 15. A method of treating Tay Sachs disease or one or more symptoms associated with Tay Sachs disease in a subject in need thereof comprising: administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months. 16. The method of claim 15, wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day. 17. A method of treating Sandhoff disease or one or more symptoms associated with Sandhoff disease in a subject in need thereof comprising: administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months. 18. The method of claim 17, wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day. 19. A method of treating Niemann Pick Type C disease or one or more symptoms associated with Niemann Pick Type C disease in a subject in need thereof comprising: administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months. 20. The method of claim 17, wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day.